High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.

The study authors tested the risk-reducing effects of ocrelizumab compared with interferon β-1a for treatment of multiple sclerosis disability accumulation, with ocrelizumab showing better results in ...

In a nationwide, retrospective, population-based cohort study, data from the Swedish MS Registry for 7331 patients were analyzed. The adjusted risk of EDSS milestones 3.0, 4.0, and 6.0 were, ...

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

A new cellular balance test can detect a hidden inflammation in the brain, helping physicians to spot multiple sclerosis ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

Explore the significant impact of obesity on multiple sclerosis (MS) progression, including increased symptoms, disability, and comorbidities. Learn how to manage weight effectively with professional ...

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today highlighted its 2025 ...